Shares of Glaukos (NYSE: GKOS) are soaring 5.04% in intraday trading on Friday, as the medical device company reported better-than-expected first-quarter 2025 results. The strong performance, highlighted by significant revenue growth and a narrower net loss, has boosted investor confidence in the company's prospects.
Glaukos announced Q1 2025 revenue of $106.7 million, marking a robust 25% increase from the same period last year and surpassing analyst estimates by 3.8%. The company's net loss narrowed substantially to $18.1 million, or $0.32 per share, compared to a loss of $0.82 per share in Q1 2024. This represents a 56% improvement in net loss and beat earnings per share (EPS) expectations by 21%.
Looking ahead, analysts forecast Glaukos' revenue to grow at an average rate of 20% per annum over the next three years, outpacing the projected 8% growth for the US Medical Equipment industry. This positive outlook, combined with the company's strong Q1 performance, appears to be driving today's stock surge despite a 12% decline over the past week.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。